61 completed, 11 terminated, 5 unknown, 4 withdrawn. 83 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 83 | Completed 61, Terminated 11, Unknown 5, Withdrawn 4, Recruiting 2 |
| Phase 2 | 5 | Completed 3, Terminated 1, Unknown 1 |
Follow Dyslipidemia: new trials by email Literature Review of Dyslipidemia trials Research Report on Dyslipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia JW0108 + C2407, JW0108 + C2407 placebo - Dyslipidemia | Phase 3 | Completed | JW Pharmaceutical | 145 | 2025-04-03 | 2025-09-03 |
| Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia JW0104+C2402, JW0104+C2403, C2402 - Hypertension, Dyslipidemia | Phase 3 | Recruiting | JW Pharmaceutical | 162 | 2024-12-02 | 2025-09-09 |
| Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia CMG190303(Dapagliflozin/Rosuvastatin), Comparator 1: Dapagliflozin/Rosuvastatin placebo, Rosuvastatin/Dapagliflozin placebo - Dyslipidemia, Type 2 Diabetes | Phase 3 | Recruiting | CMG Pharmaceutical Co. Ltd | 240 | 2024-04-19 | 2026-01-15 |
| Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia BERLIM 25/10 association, EMPAGLIFLOZIN, ROSUVASTATIN CALCIUM - Type 2 Diabetes Mellitus, Dyslipidemia | Phase 3 | Unknown | EMS | 240 | 2023-03-01 | 2022-08-05 |
| To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension LivaloVA, LivaloV, VA - Dyslipidemia, Hypertension | Phase 3 | Completed | JW Pharmaceutical | 155 | 2021-11-15 | 2024-03-15 |
| Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment Cipros 10 association, Crestor 10 mg - Hypertriglyceridemia, Dyslipidemia | Phase 3 | Completed | EMS | 146 | 2021-01-29 | 2025-12-08 |
| Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia. Valsartan 160mg + Rosuvastatin 20mg, Valsartan 320mg + Rosuvastatin 20mg, Diovan® 160mg + Crestor® 20mg - Hypertension, Dyslipidemia | Phase 3 | Withdrawn | EMS | 2019-10-01 | 2021-02-24 | |
| Dyslipidemia of Obesity Intervention in Teens Pitavastatin, Placebo - Dyslipidemia, Obesity | Phase 3 | Completed | Carelon Research | 122 | 2018-05-01 | 2024-07-05 |
| Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia Fimasartan/Amlodipine, Rosuvastatin, Fimasartan/Amlodipine, Fimasartan, Rosuvastatin - Essential Hypertension, Dyslipidemia | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 138 | 2017-05-29 | 2019-06-10 |
| Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) K-877, Placebo - Type2 Diabetes, Dyslipidemia | Phase 3 | Terminated | Kowa Research Institute, Inc. | 10544 | 2017-03-23 | 2025-09-25 |
| Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries Evolocumab - Dyslipidemia | Phase 3 | Terminated | Amgen | 1600 | 2017-03-13 | 2024-05-29 |
| Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia Telmisartan + Amlodipine + Rosuvastatin, Telmisartan + Amlodipine, Telmisartan + Rosuvastatin - Hypertension, Dyslipidemia | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 129 | 2016-10-07 | 2018-02-01 |
| Capsaicin Effect on Cytokines Profile in Dyslipidemia Capsaicin, Magnesia calcinada - Dyslipidemia, Overweight or Obesity | Phase 2 / Phase 3 | Unknown | University of Guadalajara | 17 | 2016-10-01 | 2016-07-19 |
| Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension Evolocumab - Dyslipidemia | Phase 3 | Completed | Amgen | 5035 | 2016-09-02 | 2023-04-07 |
| Bococizumab HIV Evaluation (B-HIVE) Study Bococizumab, Placebo - Dyslipidemia, Cardiovascular Disease | Phase 3 | Terminated | University of California, San Francisco | 11 | 2016-08-01 | 2019-06-19 |
| Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia NK-104-CR, Livalo® IR, Placebo (for NK-104-CR) - Hyperlipidemia, Dyslipidemia | Phase 3 | Withdrawn | Kowa Research Institute, Inc. | 2016-02-01 | 2021-05-10 | |
| Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia Metformin + Rosuvastatin, Metformin + placebo, placebo + Rosuvastatin - Type 2 Diabetes, Dyslipidemia | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 237 | 2016-01-15 | 2018-07-06 |
| Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia NK-104-CR, Placebo, Livalo - Hyperlipidemia, Dyslipidemia | Phase 3 | Withdrawn | Kowa Research Institute, Inc. | 2016-01-01 | 2021-05-10 | |
| Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes YH14755, Metformin, Rosuvastatin - Dyslipidemia, Type II Diabetes | Phase 3 | Completed | Yuhan Corporation | 249 | 2015-11-04 | 2018-10-03 |
| The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin Red yeast rice and atorvastatin, Atorvastatin alone - Dyslipidemia, Atherosclerosis | Phase 3 | Unknown | Wenzhou Medical University | 240 | 2015-11-01 | 2024-08-06 |
Showing 20 of 83. Sign in to see all of them.
Dyslipidemias (83) · Hypercholesterolemia (17) · Diabetes Mellitus, Type 2 (13) · Hypertension (12) · Obesity (10) · Hyperlipidemias (8) · Coronary Disease (6) · Cardiovascular Diseases (4) · Diabetes Mellitus (3) · Atherosclerosis (2) · Coronary Artery Disease (2) · Hypertriglyceridemia (2) · Inflammation (2) · Insulin Resistance (2) · Metabolic Syndrome (2)
Lipid Metabolism Disorders (83) · Metabolic Diseases (83) · Nutritional and Metabolic Diseases (83) · Cardiovascular Diseases (20) · Glucose Metabolism Disorders (20) · Vascular Diseases (20) · Endocrine System Diseases (16) · Hyperlipidemias (14) · Diabetes Mellitus (13) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (11) · Body Weight (10) · Nutrition Disorders (10) · Overnutrition (10) · Overweight (9)
Atorvastatin (16) · Rosuvastatin Calcium (16) · Simvastatin (11) · pitavastatin (10) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (7) · Fenofibrate (6) · Metformin (6) · Niacin (4) · evolocumab (4) · MK-0524 (3) · Rimonabant (3) · Valsartan (3) · fenofibric acid (3) · torcetrapib (3) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (2)
Abbott (7) · Kowa Research Europe (7) · Merck Sharp & Dohme LLC (6) · Amgen (4) · AstraZeneca (4) · JW Pharmaceutical (4) · EMS (3) · Kowa Research Institute, Inc. (3) · Pfizer (3) · Sanofi (3) · Solvay Pharmaceuticals (3) · Daewoong Pharmaceutical Co. LTD. (2) · Novartis (2) · Providence VA Medical Center (2) · Takeda (2)
United States (31) · South Korea (14) · Poland (12) · Denmark (11) · Germany (11) · Netherlands (11) · Canada (10) · Italy (10) · Russia (10) · Spain (10) · Sweden (10) · United Kingdom (10) · Australia (8) · Finland (8) · India (7)
Dragos Budinski, Med Dr. (5) · Dick C Chan, PhD (2) · Dragos Budinski, MD (2) · Maureen Kelly, MD (2) · Roopal Thakkar, MD (2) · Wen-Chih Wu, MD (2) · Aruna Pradhan, MD (1)
PMID 18783301, PMID 20136164, PMID 20573750, PMID 21174145, PMID 21518985, PMID 22263674, PMID 33078867, PMID 16291982, PMID 16990155, PMID 17416370, PMID 17533211, PMID 18509206, PMID 18996523, PMID 19116237, PMID 19301936, PMID 19331435, PMID 19365563, PMID 19407658, PMID 19785568, PMID 20080236, PMID 20837834, PMID 20953684, PMID 21874537, PMID 21874538, PMID 22021025, PMID 22622962, PMID 22683042, PMID 23891363, PMID 25140396, PMID 25173752, PMID 25179289, PMID 25816050, PMID 28477848, PMID 28478132, PMID 28859947, PMID 28927706, PMID 29133605, PMID 29454678, PMID 29530884, PMID 29626068, PMID 29898218, PMID 30342298, PMID 30540337, PMID 30586750, PMID 30660196, PMID 31116355, PMID 31196453, PMID 32312223, PMID 32347885, PMID 32347887
2005 (3), 2004 (1), 2014 (1), 2015 (1), 2016 (1)